Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$31.05
Change (%) Stock is Up 1.49 (5.04%)
Volume452,851
Data as of 12/18/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, Calif. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 95 employees.More >>

Recent NewsMore >>
DateTitle 
11/17/14Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)
-- Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants -- -- Data Presented Today during American Heart Association 2014 Scientific Sessions: "Clinical Science: Special Reports" Session -- SOUTH SAN FRANCISCO, Calif., PRINCETON, N.J., and NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA), Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced resul... 
Printer Friendly Version
11/10/14Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provides a corporate update and reports its financial results for the quarter ended September 30, 2014. "The third quarter marked another successful period of execution for Portola as we achieved a number of milestones across our three wholly-owned clinical programs. We announced positive Phase 3 study results with our universal Factor Xa inhibitor... 
Printer Friendly Version
11/06/14Portola Pharmaceuticals Announces Upcoming Presentations at the American Society of Hematology 2014 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that its programs in thrombosis and hematology will be highlighted in poster sessions at the upcoming American Society of Hematology (ASH) Annual Meeting, which is taking place from December 6-9 in San Francisco. Presentations will include results from a Phase 2 proof-of-concept study of andexanet alfa, an FDA-designated breakthrough therapy and potential first-in-class Factor Xa i... 
Printer Friendly Version
11/06/14Portola Pharmaceuticals to Present at the Credit Suisse 2014 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, at 9:30 a.m. Mountain Time in Phoenix. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals i... 
Printer Friendly Version
11/03/14Portola Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Monday, November 10, 2014
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2014 and provide a general business overview on Monday, November 10, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (877) 415-3183 from the U.S. and Canada, or +1(857)... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.